Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus platinum-etoposide for advanced pulmonary LCNEC
MOH_2021-12-19_010485Phase 2Not yet recruiting
- Sponsor
- דר אליזבטה דודניק
- Start
- Dec 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC), sponsored by דר אליזבטה דודניק. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)
Beyond the preview
Go deeper on MOH_2021-12-19_010485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-19_010485.